Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer

Lung Cancer
04/10/2020

Chin Med J (Engl). 2020 Sep 30. doi: 10.1097/CM9.0000000000001120. Online ahead of print.

NO ABSTRACT